The US Food and Drug Administration is urgently seeking patients that have experienced preterm birth with the market now devoid of treatments and a workshop on developing new therapies upcoming.
A 30 November post on X, formerly known as Twitter, from the FDA Patient Affairs Office seemed ominous: “US...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?